The eradication of Helicobacter pylori reduces the risk of gastric cancer. A clear understanding of the factors underlying mixed infection with multiple clarithromycin-susceptible and clarithromycin-resistant H. pylori strains is necessary to design more effective therapies against H. pylori. We aimed to assess how the abundance and prevalence of H. pylori strains vary after clarithromycin-based eradication therapy. Using gastric wash samples, which represent the entire stomach, we sequentially analyzed the abundance and prevalence of H. pylori DNA by 23S ribosomal RNA pyrosequencing before and 1, 2, and 3 years after eradication therapy. Low levels of H. pylori DNA were still detectable at the first-year follow-up in all samples with negative post-treatment urea breath test results. The abundance of H. pylori DNA decreased significantly until the 2-year follow-up, but it switched to an increase at the 3-year follow-up. Importantly, the ratio of the prevalence of mutant strains to the prevalence of wild-type strains had already increased at the first-year follow-up and continued to increase, suggesting the selection and growth of clarithromycin-resistant strains during the follow-up periods. Being sensitive and representative, our assay will be useful in effectively addressing gastric cancer development by enhancing the long-term success of intervention strategies and consecutive surveillance for H. pylori eradication.
Introduction
The eradication of Helicobacter pylori infection reduces the risk of recurrent peptic ulcer diseases and the development of gastric adenocarcinoma. [1] [2] [3] [4] [5] [6] It is now widely accepted that clarithromycin (CAM) resistance among H. pylori strains has been increasing worldwide and is the most important factor responsible for the failure of H. pylori eradication. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Various molecular methods have been developed to detect CAM resistance in H. pylori isolates in clinical specimens, such as biopsy samples and feces. 13, 15, 16 These assays for detecting CAM resistance in H. pylori are based on the detection of mutations in the 23S ribosomal RNA (rRNA) gene.
In an earlier study, 39% of patients with CAM-resistant H. pylori were reported to be infected with both CAMresistant and CAM-susceptible H. pylori. 20 Frequent mixed infections with multiple H. pylori strains in the human stomach have also been reported. [21] [22] [23] [24] [25] Because mixed infections are common and one of the reasons for unsuccessful therapy, an accurate quantitative test for the presence of CAM-resistant H. pylori is necessary for successful eradication therapy. However, gastric biopsy is a topical procedure in which only a small portion of tissue is excised during endoscopy. One study showed two different H. pylori strains to have variable distribution among biopsy sites in a H. pylori-infected individual, 22 which indicates that biopsy-based analysis might underestimate mixed infection detection.
In contrast, gastric wash samples are collected from the whole stomach using saline during endoscopy. 26 Because abundant cells are exfoliated from the gastric mucosa during washing, undamaged human and H. pylori DNA can be recovered from the wash and be assayed by sensitive quantitative techniques. [26] [27] [28] We recently developed a pyrosequencing-based method for the quantification of H. pylori genotypes using gastric washes and found that many patients carried mixed infection with CAM-susceptible (wild-type) and CAM-resistant (A2143G or A2144G mutant) H. pylori. 29 These data suggest that our method can detect mixed infections with higher sensitivity than biopsybased methods, because H. pylori DNA can be extracted from gastric washes, which reflect the whole stomach.
In the case of mixed infections, CAM-resistant H. pylori may be selected for survival after CAM-based eradication therapy, which might result in the failure of therapy. However, it remains unknown how the abundance and prevalence of H. pylori strains vary after eradication therapy. A better understanding of mixed infection with multiple H. pylori strains is necessary to design more effective therapies against H. pylori. In this prospective study, using gastric wash samples from patients with early gastric cancer who had undergone endoscopic resection, we sequentially analyzed the abundance and prevalence of H. pylori DNA by 23S rRNA pyrosequencing before and 1, 2, and 3 years after CAM-based triple eradication therapy.
Materials and methods

Clinical samples
In this prospective study, 19 patients with early gastric cancer who had undergone endoscopic resection were diagnosed with H. pylori infection at the time of endoscopic resection. All the patients (13 males and 6 females) were diagnosed as H. pylori infection-positive by the H. pylori IgG assay, rapid urease test, or urea breath test (UBT). The patients received CAM-based triple eradication therapy. Successful eradication was confirmed by negative results of the UBT 1 month or more after the eradication. Patients were followed-up annually by endoscopic evaluation and collection of gastric wash samples at 1 (n = 14), 2 (n = 14), and 3 (n = 13) years after endoscopic resection and H. pylori eradication therapy. Several patients could not be followed-up annually by endoscopic evaluation at all three timepoints because of non-medical reasons or medical reasons other than gastrointestinal disease. Samples were immediately frozen at −80°C and DNA was extracted as previously reported. The study was conducted in accordance with all the rules and regulations of the St. Marianna University School of Medicine Institutional Review Board (#1929), and written informed consent was obtained from each patient ( Table 1 ).
Sample collection of gastric washes
Approximately 10 min prior to endoscopy, patients were asked to swallow 100 mL water containing 80 mg dimethylpolysiloxane (GASCON; Kissei Pharmaceutical Co., Ltd., Matsumoto, Japan), 1 g sodium bicarbonate, and 20,000 units pronase (Pronase MS; Kaken Pharmaceutical Co., Ltd., Tokyo, Japan). Gastric washes were collected in specimen containers (No. 111219; Forte Grow Medical, Tochigi, Japan), which were directly fitted to the endoscope modulator. Gastric washes were manually aspirated under vacuum through the suction channel of the endoscope and centrifuged immediately, and resulting pellets were frozen at −80°C. Disposable sample collection tubes, connector tubes, and other endoscopic devices were used. The endoscope was washed after each procedure according to the guidelines, using 0.55% DISOPA (Johnson and Johnson, Langhorne, PA, USA) and an automatic washing machine.
DNA extraction
DNA was extracted from gastric wash samples by phenol chloroform. Briefly, frozen pellets from gastric washes were resuspended in 10% sodium dodecyl sulfate (SDS) and proteinase K, mixed vigorously, and incubated at 37°C for 6 h. Samples were then mixed vigorously for approximately 30 s with one volume of 25:24:1 phenol: chloroform:isoamyl alcohol and centrifuged at room temperature for 5 min at 16,000×g. The aqueous layer was then transferred to a fresh tube and extracted in the same manner another two times. Final extracts were then mixed with 100% ethanol, centrifuged at 4°C for 5 min at 16,000×g, and stored at -20°C overnight to precipitate DNA. Precipitates were collected by centrifugation, washed with 70% ethanol, and centrifuged at 4°C for 2 min at 16,000×g. As much of the supernatant was removed as possible, and pellets were resuspended in 500 μL Tris-EDTA buffer. Final DNA concentration and quality were measured on a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
Abundance of H. pylori 23S rRNA in gastric wash samples
We analyzed gastric wash DNA samples by SYBR Green real-time polymerase chain reaction (PCR), with H. pylori 23S rRNA as target and human GAPDH as reference. It was necessary to normalize abundance of H. pylori 23S rRNA gene using total volume of gastric washes. However, it was difficult to accurately quantify total volume of gastric washes obtained in each endoscopy. Alternatively, the amounts of DNA of human cells exfoliated from the gastric mucosa during washing reflect total volume of gastric washes. 26, 29 Therefore, we normalized abundance of H. pylori 23S rRNA gene using human GAPDH gene instead of other bacterial gene. H. pylori 23S rRNA was amplified with sense primer "acgagatgggagctgtctcaacc" and antisense primer "agcattgtcctgcctgtggataac," while human GAPDH was amplified with sense primer "cgagatccctccaaaatcaa" and antisense primer "ctgcaaatgagcctacagca." Reactions were performed on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's instructions. Data were analyzed in SDS2.1 by comparative cycle threshold (ΔCt).
Quantitative pyrosequencing analysis of multiple H. pylori strains
Pyrosequencing enables quantitative analysis of the abundance of polymorphisms at a given site. 23S rRNA was amplified and biotinylated by nested PCR from gastric wash samples. In the first reaction, a 255 bp fragment was amplified with sense primer "acgagatgggagctgtctcaacc" and antisense primer "agcattgtcctgcctgtggataac." Amplification products were then used as a template in the second reaction to amplify a 90 bp fragment with sense primer "gaggtgaaaattcctcctacccgcg" and antisense primer "gcgcatgatattcccattagcagtgc." Reactions consisted of touchdown PCR with denaturation at 95°C for 30 s, annealing at appropriate temperatures for 30 s, and extension at 72°C for 30 s. Finally, amplification products were analyzed by pyrosequencing on a Pyromark Q24 (QIAGEN, Valencia, CA, USA) using primer "acccgcggcaagacg." Sequence to analyze A2143V is "GVAAGACCCCGTGG ACCTTTACTACAA" and A2144R "RAGACCCCGTGG ACCTT TACTACAAC."
Results
H. pylori abundance in gastric wash samples
We clinically diagnosed 19 patients in whom H. pylori had been "successfully eradicated" on the basis of the UBT, because all results showed values below the cutoff line (<2.5‰; Table 1 ). Interestingly, the values showed some variance among patients, although they were below the cutoff line (0.0‰-2.1‰, mean 0.77‰ ± 0.64‰). We used real-time PCR to estimate the abundance of H. pylori DNA in gastric wash samples, as measured by the abundance of 23S rRNA gene relative to the abundance of human GAPDH gene. Abundance of H. pylori 23S rRNA gene significantly decreased 1 year after H. pylori eradication, but none of the samples showed a value of 0 (1242.0 ± 1313.0 to 367.6 ± 467.2, p = 0.02; Figure 1 ). The abundance of H. pylori DNA was the lowest at the 2-year follow-up, but it was found to have increased at the 3-year follow-up.
Measurement of the ratio of H. pylori strains before and after eradication therapy
Representative pyrograms were shown in Figure 2 . The frequencies of the A2143G, A2143C, and A2144G mutant H. pylori strains were examined using gastric wash samples at four timepoints (Table 1 , Figure 3(a) and (b) ). None of the samples showed the A2143C mutant, whereas both A2143G and A2144G mutant strains were detected before eradication therapy. The prevalence of the A2143G and A2144G mutants increased after eradication therapy, and the prevalence at 3 years was significantly higher than that before treatment (16.8% ± 22.6% to 50.6% ± 14.6% for A2143G, p = 0.0001; 34.6% ± 35.4% to 73.7% ± 23.4% for A2144G, p = 0.002). Moreover, there was a significant correlation between the frequencies of A2143G and A2144G mutants at the timepoint of 3 years (r = 0.96, p = 0.0001; Figure 3 (c)). 
Mutant H. pylori strains were inversely correlated with age
Both mutant strains A2143G and A2144G were inversely correlated with age at the timepoint of 3 years (A2143G, r = −0.74, p = 0.005; A2144G, r = −0.68, p = 0.013; Figure  4 (a) and (b)).
Discussion
Using gastric wash DNA, we obtained a quantitative timecourse analysis of the abundance and prevalence of H. pylori genotypes before and after CAM-based eradication therapy ( Figure 5 ). Low levels of H. pylori DNA were still detectable at the first-year follow-up in all samples with negative post-treatment UBT results. The abundance of H. pylori DNA decreased significantly until the 2-year follow-up, but it had increased at the 3-year follow-up. These results suggest that our PCR assay is more sensitive than conventional methods and that it is necessary to monitor the impact of treatments in the follow-up period even if H. pylori is found to be successfully eradicated in patients on the basis of conventional tests after eradication therapy. Both A2143G and A2144G mutant strains were detected before CAM-based eradication therapy. Moreover, the ratio of the prevalence of mutant strains to that of the wildtype strain was found to have already increased significantly 1 year after eradication therapy and continued to increase, suggesting that CAM-resistant strains survived more easily after treatment. Although the abundance of CAM-resistant strains was low after eradication therapy, these strains increased and were found to be enriched in the follow-up period, leading to persistent H. pylori infection and eventually to the recrudescence (clinically detectable recurrence) of H. pylori infection after successful eradication therapy. In an earlier qualitative study, Matsuoka et al. 21 suggested that a small number of CAMresistant strains could emerge spontaneously in the stomach and that resistant strains are not formed but selected by CAM administration.
Both the mutant H. pylori strains A2143G and A2144G were inversely correlated with age at the timepoint of 3 years, indicating that the prevalence of CAM-resistant strains is on the rise in patients of younger age. This might be attributed to the overuse of macrolides in Japan. In fact, in Europe, the use of macrolides for various infections over the past 2 decades, especially long-standing macrolides, has contributed to the selection of resistant H. pylori strains. 30 Our assay enables the detection of H. pylori DNA at a higher sensitivity than that of conventional tests, and it can quantify multiple genotypes. Failure of H. pylori eradication is one of the independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer. 31 Hence, our assay is useful to (1) diagnose H. pylori infection, including mixed infections; (2) choose personalized treatment strategies; and (3) monitor the impact of the treatment in the follow-up period, especially for high-risk patients.
Our assay has several advantages, such as being simple and safe because it circumvents the need for biopsy, as well as being quantitative, rapid, economical, and representative of the whole stomach. Moreover, it is possible to analyze gastric wash DNA for both H. pylori genotypes and human cancer-related genes. [26] [27] [28] [29] Therefore, our assay is feasible for clinical application and should thus be validated in large-scale clinical trials. We believe that the longterm success of preventing gastric cancer development lies in effective H. pylori eradication interventions and consecutive surveillance, which can be facilitated by the application of sensitive and accurate detection techniques. 
